Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON45312
NL-OMON45312
Completed
Not Applicable

*Dutch Marines study on Rabies antibody response after Boostering an intradermal pre-exposure scheme (MaRaBoo study)* - MaRaBoo study

Academisch Medisch Centrum0 sites24 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRabies10047438

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rabies
Sponsor
Academisch Medisch Centrum
Enrollment
24
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Trial ended prematurely

Registry
who.int
Start Date
TBD
End Date
February 4, 2019
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Healthy military volunteers that received a completed intradermal immunization last year or 2 years ago.

Exclusion Criteria

  • •\- Age \< 18 years;
  • •\- No previous booster immunization;
  • •\- No previous post\-exposition treatment with HRIG;
  • •\- Potential deployment to rabies endemic area within study period ;
  • •\- Presence of a serious medical history with a potential effect on the immune system such
  • •as diabetes mellitus, HIV, functional or hyposplenia/asplenia;
  • •\- Allergies to one of the components of the rabies vaccine such as chicken egg protein,
  • •polygeline, hypersensitivity to neomycin, chlortetracycline, amphotericin B and other
  • •antibiotics of the same class;
  • •\- Use of mefloquine or chloroquine during the study period ;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Rabies antibody respons after booster vaccination, &gt; 10 years after pre-exposure scheme (RAR-boost study)Rabies10047438
NL-OMON47356Academisch Medisch Centrum29
Completed
Not Applicable
Validation of the Dutch version of the Hip Outcome Score
NL-OMON47747Reinier de Graaf Groep136
Completed
Not Applicable
An international, non-drug interventional, real-world cohort of PAH patients newly initiating PAH therapy with guideline-directed assessments of disease severityIncreased bloodpressure in the arteries of the lungPulmonary arterial hypertension1001928010038716
NL-OMON52230Actelion Pharmaceuticals12
Completed
Not Applicable
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NL-OMON49382AbbVie B.V.2
Completed
Phase 2
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158
NL-OMON54921IMARA, Inc.15